Investment Rating - The report initiates coverage with a "Buy" rating for the company [3][9] Core Insights - The company is a pioneer in the ultrasound field, focusing on portable and intelligent solutions, with a strong outlook for external collaborations [2][8] - The company has a comprehensive product lineup that includes high-end ultrasound machines and portable devices, which are competitive in both domestic and international markets [8][60] - The financial projections indicate steady revenue growth, with expected revenues of 5.17 billion, 6.21 billion, and 7.45 billion yuan for 2025, 2026, and 2027 respectively, alongside net profits of 1.46 billion, 1.82 billion, and 2.29 billion yuan [7][9] Summary by Sections 1. Company Overview - Founded in 1996, the company has focused on ultrasound technology, holding over 400 intellectual property rights and exporting products to more than 100 countries [18][21] - The company has established R&D centers in both China and the US, and has been involved in significant national research projects [18] 2. Market Potential - The global ultrasound market is projected to grow, with a compound annual growth rate (CAGR) of 9% expected from 2020 to 2024 [43] - The domestic ultrasound market is also expanding, with significant breakthroughs from local companies [47] 3. Product Development - The company has developed a complete range of ultrasound products, including high-end and portable devices, which are recognized for their performance and innovation [60][67] - The SonoFamily series includes advanced products like XBit90, SonoMax, SonoAir, and SonoEye, which leverage AI technology for enhanced diagnostic capabilities [60][66] 4. Financial Performance - The company has shown stable financial performance, with a projected revenue of 4.69 billion yuan in 2024, despite a slight decline due to external factors [27][32] - The gross margin remains stable at around 59%, with a low debt ratio of 11% as of Q3 2025 [34][38] 5. Strategic Collaborations - The company is actively pursuing external collaborations, including ODM partnerships with major global firms like Philips and the Gates Foundation, which are expected to enhance growth prospects [79][81]

该股主要指标及行业内排名如下： 证券之星消息，截至2025年12月11日收盘，美好医疗(301363)报收于20.95元，上涨2.2%，换手率 1.56%，成交量5.82万手，成交额1.22亿元。 12月11日的资金流向数据方面，主力资金净流入1507.1万元，占总成交额12.35%，游资资金净流出 679.95万元，占总成交额5.57%，散户资金净流出827.15万元，占总成交额6.78%。 近5日资金流向一览见下表： 美好医疗融资融券信息显示，融资方面，当日融资买入1525.75万元，融资偿还1188.76万元，融资净买 入336.99万元。融券方面，融券卖出2500.0股，融券偿还1100.0股，融券余量3.22万股，融券余额67.42 万元。融资融券余额1.39亿元。 近5日融资融券数据一览见下表： 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5. ...

证券日报网讯12月11日，美好医疗（301363）在互动平台回答投资者提问时表示，截至2025年12月10 日，公司股东总户数为15607户。 ...

证券之星消息，美好医疗(301363)12月11日在投资者关系平台上答复投资者关心的问题。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 美好医疗回复：您好，截至2025年12月10日，公司股东总户数为15,607户。 投资者提问：请及时回复12月10日之股东人数。感谢！ ...

Group 1 - The 2025 Computing Power Industry Ecological High-Quality Conference will be held on December 11 [1] - The Hongmeng Office Industry Summit will also take place on December 11 [2] - Huillen Crystal will resume trading on December 11, with its stock name changed to "ST Huillen" and subject to risk warnings [2] - ST Kevin will resume trading on December 11, with its stock name changed to "Caesar Culture" and an increase in the daily trading limit from 5% to 10% [2] Group 2 - On December 10, China successfully launched nine satellites using the Lijian-1 Yao-11 rocket [3] - The Ministry of Finance issued 7 billion RMB of government bonds in Hong Kong, with a subscription multiple of 5.22 times [3] - In November 2025, China's consumer price index rose by 0.7% year-on-year, with urban prices increasing by 0.7% and rural prices by 0.4% [3] Group 3 - The Shanghai Municipal Government released the implementation plan for the childcare subsidy system, providing 3,600 RMB per child per year for eligible families [4] - The IMF raised China's economic growth forecast for this year to 5%, an increase of 0.2 percentage points from the previous report [4] - From January to November, China's railway construction investment reached 753.8 billion RMB, a year-on-year increase of 5.9% [4] Group 4 - The Ministry of Finance plans to issue special government bonds with a total face value of 75 billion RMB on December 12, 2025 [5] - The China Computing Power Platform's local zone has officially launched, marking a significant step in the construction of a national integrated computing power network [5] Group 5 - Hainan's Free Trade Port development plan emphasizes high-standard construction and aims to leverage its geographical and natural resource advantages [6][7] - The Hainan Free Trade Port will officially start its full island closure operation on December 18, benefiting the international tourism consumption center [7] Group 6 - Alibaba's Qianwen AI application has surpassed 30 million monthly active users within 23 days of public testing, becoming one of the fastest-growing AI applications globally [8] - The Qianwen app has introduced new features, enhancing its capabilities beyond simple interactions [8] Group 7 - Shanghai's first low-altitude drone medical sample delivery route has been launched, aiming to enhance healthcare efficiency [9] - The low-altitude economy is seen as a preferred direction for local economic expansion, potentially generating a multiplier effect on investments [9] Group 8 - CATL plans to register and issue bonds not exceeding 10 billion RMB [10] - Century Huatong's subsidiary holds 1,958,870 shares of Moer Thread [11] - Muxi Co. reported that 20,349 shares were abandoned by online investors [12] - Lens Technology intends to acquire 100% of Peimei International, expanding into AI computing infrastructure [13] Group 9 - Jereh Group emphasizes its capabilities in power generation equipment for various sectors, including data centers and oil and gas development [20] - The company has established a global supply chain and partnerships with major gas turbine manufacturers [20]

【美好医疗透露脑机接口业务进展，目前收入规模较小】12月10日，美好医疗在互动平台称，脑机接口 产品成熟度和应用场景随下游客户产品完善而性能提升。公司正与下游脑机接口客户深入合作，助力其 从实验室研发到批量出货的商业化转化。不过，目前相关业务产生的收入规模较小。 本文由 AI算法生成，仅作参考，不涉投资建议，使用风险自担 ...

该股主要指标及行业内排名如下： 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5.89%；单季度扣非净利润 9270.68万元，同比上升9.56%；负债率11.43%，投资收益490.31万元，财务费用-2739.1万元，毛利率 39.34%。美好医疗（301363）主营业务：为全球医疗器械企业提供从产品设计开发到批量生产交付的 全流程一站式服务。 证券之星消息，截至2025年12月10日收盘，美好医疗(301363)报收于20.5元，上涨0.2%，换手率 1.06%，成交量3.96万手，成交额8104.59万元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的 ...

人民财讯12月10日电，美好医疗（301363）12月10日在互动平台表示，脑机接口产品的成熟度和应用场 景随着下游客户产品的成熟和完善性能不断提高。公司正与下游脑机接口客户深入开展产品合作，协助 客户实现从实验室研发到批量出货的高效商业化转化，目前相关业务产生的收入规模较小。 ...

美好医疗在互动易平台回复投资者提问时表示，目前，侵入式脑机接口产品在植入材料选择、生物相容 性、自供电技术等关键领域与人工耳蜗高度相通。公司在脑机接口业务领域有着长期业务布局。具体来 看，在侵入式脑机接口领域，持续提升植入体组件的长期稳定性与生物相容性，推进材料安全性及排异 反应等方面的测试与优化，提供具备长期植入性、低排异、可量产、高可靠性的产品解决方案，并为非 植入组件提供集成化、小型化、便携式的产品研发制造支持。在半侵入式脑机接口领域，提供长期植入 产品方案，并配套相关手术辅助器械与耗材。在非侵入式脑机接口领域，提供小型化、便携性强、质量 稳定的产品组件与耗材。 美好医疗(301363)12月10日在互动易平台表示，公司已进入侵入式脑机接口产品的核心供应链，正与下 游脑机接口客户深入开展产品合作，协助客户实现从实验室研发到批量出货的高效商业化转化，目前已 产生小规模销售收入。未来将紧密追踪产业发展需求，全品类布局非侵入式、半侵入式、侵入式脑机接 口产品的核心供应链。 脑机接口产品的成熟度和应用场景随着下游客户产品的成熟和完善性能不断提高。美好医疗表示，公司 正与下游脑机接口客户深入开展产品合作，协助客户 ...

格隆汇12月10日丨美好医疗(301363.SZ)在互动平台表示，脑机接口产品的成熟度和应用场景随着下游 客户产品的成熟和完善性能不断提高。公司正与下游脑机接口客户深入开展产品合作，协助客户实现从 实验室研发到批量出货的高效商业化转化，目前相关业务产生的收入规模较小。 ...